Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciprofloxacin + ornidazole is a fixed-dose combination of two antimicrobial agents used to treat a broad range of bacterial and protozoal infections, particularly those involving the gastrointestinal tract, urinary tract, respiratory system, and gynecological or pelvic regions. Ciprofloxacin is a fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and leading to bacterial cell death. Ornidazole is an antiprotozoal and antibacterial agent from the nitroimidazole class; it works by damaging the DNA of anaerobic bacteria and protozoa, resulting in their death. This combination provides synergistic coverage against both aerobic bacteria (via ciprofloxacin) and anaerobic bacteria/protozoa (via ornidazole), making it effective for mixed infections such as diarrhea (including amoebic dysentery), gynecological infections, dental infections, intra-abdominal infections, giardiasis, amoebiasis, cystitis after urological procedures in women with urinary incontinence surgery history[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciprofloxacin + ornidazole.